๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Expression of CD44 in rat liver allografts during rejection

โœ Scribed by Fujisaki, Shigeru ;Miyake, Hiroshi ;Amano, Sadao ;Nakayama, Hisashi ;Oida, Takatsugu ;Takizawa, Hidehiro

Publisher
Springer
Year
1998
Tongue
English
Weight
287 KB
Volume
5
Category
Article
ISSN
0944-1166

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

CD40L (CD154) expression in human liver
CD40L (CD154) expression in human liver allografts during chronic ductopenic rejection
โœ Gaweco, Anderson S. ;Wiesner, Russell H. ;Yong, Sherri ;Krom, Ruud ;Porayko, Mic ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› Wiley (John Wiley & Sons) ๐ŸŒ English โš– 226 KB

The CD40-CD40L (CD154) interaction plays a pivotal role in the effector mechanisms of allograft rejection. Blockade of the CD40/CD40L costimulatory pathway prevents the development of chronic allograft rejection in several animal transplant models. The relevance of in situ CD40 and CD40L expression

Enhanced expression of cytokine-induced
Enhanced expression of cytokine-induced neutrophil chemoattractant in rat hepatic allografts during acute rejection
โœ Y Yamaguchi; O Ichiguchi; F Matsumura; E Akizuki; T Matsuda; K Okabe; S Yamada; ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 319 KB

The kinetics of messenger RNA (mRNA) and protein levels pounds. 1 Thus, neutrophils were thought to be relevant only of cytokine-induced neutrophil chemoattractant (CINC) in rat to the efferent limb of the immune response. However, it has hepatic allografts during acute rejection were investigated.

Intragraft CD45 RO gene expression is an
Intragraft CD45 RO gene expression is an early marker to detect small bowel allograft rejection in rats
โœ Pengzhi Wang; Liwei Zhu; Tong Liu; Xijun Zhang; Yujie Qiu ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 28 KB

Wistar Furth (WF) intestinal allografts were transplanted into Sprague-Dawley (SD) rats. Recipients were randomly allocated into the following groups: (1) no treatment; (2) cyclosporine (CsA) 6 mg/kg/day, daily, subcutaneously (s.c.; fulldose therapy); (3) CsA 3 mg/kg/day, daily, s.c. (half-dose the